Cell Med X Corp. CMXC
We take great care to ensure that the data presented and summarized in this overview for Cell MedX Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CMXC
Top Purchases
Top Sells
About CMXC
Cell MedX Corp., a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is based in Carson City, Nevada.
Insider Transactions at CMXC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2023
|
David Jeffs Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
15,000,000
+8.1%
|
$0
$0.01 P/Share
|
|
Dec 29
2023
|
David Jeffs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,959,726
+50.0%
|
$0
$0.01 P/Share
|
|
Dec 29
2023
|
Richard Jeffs > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,372,285
+35.93%
|
$0
$0.01 P/Share
|
|
Dec 29
2023
|
Dwayne Yaretz Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,214,285
+50.0%
|
$0
$0.01 P/Share
|
|
Dec 29
2023
|
Joao Da Costa Director |
BUY
Grant, award, or other acquisition
|
Indirect |
531,687
+20.5%
|
$0
$0.01 P/Share
|
|
Dec 29
2023
|
Amir Vahabzadeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,755,148
+48.73%
|
$0
$0.01 P/Share
|
|
Apr 06
2022
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
10,000
-0.18%
|
$0
$0.15 P/Share
|
|
Feb 07
2022
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
600
-0.01%
|
$0
$0.18 P/Share
|
|
Feb 04
2022
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
7,000
-0.13%
|
$0
$0.15 P/Share
|
|
Jan 05
2022
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
7,500
-0.14%
|
$0
$0.15 P/Share
|
|
Dec 29
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$0
$0.18 P/Share
|
|
Dec 20
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
5,000
-0.09%
|
$90,000
$18.2 P/Share
|
|
Dec 15
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
4,654
-0.08%
|
$0
$0.19 P/Share
|
|
Nov 24
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
20,000
-0.36%
|
$0
$0.17 P/Share
|
|
Sep 14
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
10,000
-0.18%
|
$0
$0.2 P/Share
|
|
Sep 09
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
10,000
-0.18%
|
$0
$0.22 P/Share
|
|
Aug 02
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
6,500
-0.12%
|
$0
$0.26 P/Share
|
|
Jul 29
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
10,000
-0.18%
|
$0
$0.26 P/Share
|
|
Jul 27
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
10,000
-0.18%
|
$0
$0.26 P/Share
|
|
Jul 23
2021
|
Bradley S Hargreaves VP Technology & Operations |
SELL
Open market or private sale
|
Direct |
351
-0.01%
|
$0
$0.28 P/Share
|